OUP Management Co., LLC
- SEC CIK
- 0001880124
- Latest filing
- Nov 9, 2023
Holdings in Q4 2022
Holdings as of Dec 31, 2022, filed Feb 2, 2023. Long positions only; changes compare share counts with Q3 2022.
- Positions
- 14
- −1 vs. Q3 2022
- Portfolio value
- $61.3M
- −$2.96M (−4.6%) vs. Q3 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| JBIOJade Biosciences, Inc. | COM | 603,762 | $17.7M | 28.9% | 00.0% | Unchanged | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 2,937,615 | $9.11M | 14.9% | 00.0% | Unchanged | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 989,232 | $8.61M | 14.1% | 00.0% | Unchanged | History |
| DICEDICE Therapeutics, Inc. | COM | 268,346 | $8.37M | 13.7% | −268,347−50.0% | Reduced | History |
| IONQIonQ, Inc. | COM | 1,177,597 | $4.06M | 6.6% | 00.0% | Unchanged | History |
| CYTCyteir Therapeutics, Inc. | COM | 2,459,572 | $4.06M | 6.6% | −10,000−0.4% | Reduced | History |
| VORVor Biopharma Inc. | COM | 374,714 | $2.49M | 4.1% | 00.0% | Unchanged | History |
| PRMEPrime Medicine, Inc. | COM | 121,255 | $2.25M | 3.7% | +121,255 | New | History |
| LENZLENZ Therapeutics, Inc. | COM | 406,308 | $1.35M | 2.2% | 00.0% | Unchanged | History |
| DTILPrecision Biosciences Inc | COM | 1,123,913 | $1.34M | 2.2% | 00.0% | Unchanged | History |
| RNACCartesian Therapeutics, Inc. | COM | 862,543 | $974.7K | 1.6% | 00.0% | Unchanged | History |
| EFTReFFECTOR Therapeutics, Inc. | COM | 1,025,697 | $438.6K | 0.7% | 00.0% | Unchanged | History |
| SPROSpero Therapeutics, Inc. | COM | 249,070 | $430.9K | 0.7% | 00.0% | Unchanged | History |
| QTTBQ32 Bio Inc. | COM | 64,000 | $80.6K | 0.1% | 00.0% | Unchanged | History |
Sold out since Q3 2022 (2)
Positions held at the end of Q3 2022 that are gone from this filing.